Octavia, Y. et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell Cardiol. 52, 1213–1225 (2012).

Article  CAS  PubMed  Google Scholar 

Henriksen, P. A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 104, 971–977 (2018).

Article  CAS  PubMed  Google Scholar 

Zamorano, J. L. et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J. 37, 2768–2801 (2016).

Article  PubMed  Google Scholar 

Armenian, S. H. et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 16, e123–e136 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Lyon, A. R. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 43, 4229–4361 (2022).

Article  PubMed  Google Scholar 

Dimarco, A. et al. ‘Daunomycin’, a new antibiotic of the rhodomycin group. Nature 201, 706–707 (1964).

Article  CAS  PubMed  Google Scholar 

Dubost, M. et al. A new antibiotic with cytostatic properties: rubidomycin [French]. C. R. Hebd. Seances Acad. Sci. 257, 1813–1815 (1963).

CAS  PubMed  Google Scholar 

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229 (2004).

Article  CAS  PubMed  Google Scholar 

Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S. & Navik, U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed. Pharmacother. 139, 111708 (2021).

Article  CAS  PubMed  Google Scholar 

Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L. & Karnofsky, D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20, 333–353 (1967).

Article  CAS  PubMed  Google Scholar 

Middleman, E., Luce, J. & Frei, E. Clinical trials with adriamycin. Cancer 28, 844–850 (1971).

Article  CAS  PubMed  Google Scholar 

Swain, S. M., Whaley, F. S. & Ewer, M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869–2879 (2003).

Article  CAS  PubMed  Google Scholar 

Arcamone, F. et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers. Cancer Treat. Rep. 60, 829–834 (1976).

CAS  PubMed  Google Scholar 

Danesi, R., Fogli, S., Gennari, A., Conte, P. & Del Tacca, M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin. Pharmacokinet. 41, 431–444 (2002).

Article  CAS  PubMed  Google Scholar 

Jain, K. K. et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. 3, 818–826 (1985).

Article  CAS  PubMed  Google Scholar 

Ryberg, M. et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 16, 3502–3508 (1998).

Article  CAS  PubMed  Google Scholar 

Toffoli, G. et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin. Cancer Res. 6, 2279–2287 (2000).

CAS  PubMed  Google Scholar 

Anderlini, P. et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 13, 2827–2834 (1995).

Article  CAS  PubMed  Google Scholar 

Ichikawa, Y. et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 124, 617–630 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marinello, J., Delcuratolo, M. & Capranico, G. Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. IJMS 19, 3480 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Qiu, Y., Jiang, P. & Huang, Y. Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention. Front. Cardiovasc. Med. 10, 1242596 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639–1642 (2012).

Article  PubMed  Google Scholar 

Chatterjee, K., Zhang, J., Honbo, N. & Karliner, J. S. Doxorubicin cardiomyopathy. Cardiology 115, 155–162 (2010).

Article  CAS  PubMed  Google Scholar 

Fang, X. et al. Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl Acad. Sci. USA 116, 2672–2680 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amgalan, D. et al. A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy. Nat. Cancer 1, 315–328 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, M. et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 138, 696–711 (2018).

Article  CAS  PubMed  Google Scholar 

Cappetta, D. et al. Doxorubicin targets multiple players: a new view of an old problem. Pharmacol. Res. 127, 4–14 (2018).

Article  CAS  PubMed  Google Scholar 

Cardinale, D., Iacopo, F. & Cipolla, C. M. Cardiotoxicity of anthracyclines. Front. Cardiovasc. Med. 7, 26 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardinale, D., Biasillo, G. & Cipolla, C. M. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr. Cardiol. Rep. 18, 51 (2016).

Article  PubMed  Google Scholar 

Franco, V. I., Henkel, J. M., Miller, T. L. & Lipshultz, S. E. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol. Res. Pract. 2011, 134679 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N. & Giordano, S. H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 25, 3808–3815 (2007).

Article  CAS  PubMed  Google Scholar 

Harbeck, N., Ewer, M. S., De Laurentiis, M., Suter, T. M. & Ewer, S. M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann. Oncol. 22, 1250–1258 (2011).

Article